<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751760</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0293</org_study_id>
    <nct_id>NCT04751760</nct_id>
  </id_info>
  <brief_title>Feasibility Study of a New Immunoglobulin E (IgE) Assay Method</brief_title>
  <acronym>LuLISA</acronym>
  <official_title>Feasibility Study of a New Immunoglobulin E (IgE) Assay Method in Urine and Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to study the feasibility of a new specific IgE assay using a&#xD;
      bioluminescence technique in a pediatric and adult allergic population. For this, we will&#xD;
      collect blood, and urine during a blood test scheduled for the follow-up of the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergy is a raising public health problem. Specific IgE assays are useful tools to&#xD;
      investigate the physiopathology of allergies. This method is achieved mainly by the ImmunoCAP&#xD;
      enzyme immunoassay technique. This is an expensive test that requires a significant amount of&#xD;
      blood. This is a limitation particularly in children. The time to get the results is long and&#xD;
      a second consultation has to be scheduled in order to communicate the results to the&#xD;
      patients. The main objective of this study is to assess the feasibility of a new specific IgE&#xD;
      assay, named LuLISA, using a bioluminescence technique in urine and blood samples from&#xD;
      pediatric and adult allergic population. This technique was recently published for the&#xD;
      quantification of IgE against two peanut allergens and needs to be extended for the detection&#xD;
      of other major allergens. A secondary objective is the evaluation of the time needed to&#xD;
      obtain results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">January 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of the the correlation of specific IgE concentrations for a given allergen analyzed using two different methods</measure>
    <time_frame>Day 0</time_frame>
    <description>specific IgE concentrations for a given allergen will be measured by both LuLISA and ImmunoCAP and the results will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the correlation between the results of specific serum and urinary IgE dosages by LuLISA</measure>
    <time_frame>Day 0</time_frame>
    <description>specific IgE concentrations for a given allergen will be measured in the sera and the urine from the same patient and the results will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the correlation between the results of specific IgE dosages in the venous blood and the capillary blood</measure>
    <time_frame>Day 0</time_frame>
    <description>specific IgE concentrations for a given allergen will be measured in the venous blood and the capillary blood from the same patient and the results will be compared</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1376</enrollment>
  <condition>Allergy and Immunology</condition>
  <arm_group>
    <arm_group_label>People with sensitization or allergy</arm_group_label>
    <description>blood and urine will be collected during a blood test scheduled for the follow-up of the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collection of blood and urine</intervention_name>
    <description>blood and urine will be collected during a blood test scheduled for the follow-up of the patient</description>
    <arm_group_label>People with sensitization or allergy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients followed at the Toulouse University Hospital and presenting sensitization or&#xD;
        allergy towards a trophallergen, an aeroallergen, hymenoptera venom or drug&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females 6 months' old or older&#xD;
&#xD;
          -  Sensitization or allergy towards a trophallergen, an aeroallergen, hymenoptera venom&#xD;
             or drug proven by:&#xD;
&#xD;
               -  positive skin test (s)&#xD;
&#xD;
               -  and / or IgE specific (s)&gt; 0.1 kUA / L&#xD;
&#xD;
               -  and / or anamnesis in favor of an allergic reaction of mediated IgE&#xD;
&#xD;
          -  Social coverage up to date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children younger than 6 months'old&#xD;
&#xD;
          -  Children's weight less than 10 kg&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients with cystic fibrosis&#xD;
&#xD;
          -  Patients with dysimmune or autoimmune pathology&#xD;
&#xD;
          -  Anamnesis in favor of a delayed allergy or a contact allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine Michelet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marine Michelet, MD</last_name>
    <phone>33-5 34 55 85 85</phone>
    <email>michelet.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine Michelet, MD</last_name>
      <phone>5 34 55 85 86</phone>
      <phone_ext>0033</phone_ext>
      <email>michelet.m@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fran√ßoise Auriol, PhD</last_name>
      <phone>561779103</phone>
      <phone_ext>0033</phone_ext>
      <email>auriol.f@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Larrey hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Guilleminault, MD</last_name>
      <phone>567771624</phone>
      <phone_ext>0033</phone_ext>
      <email>guilleminault.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgE assay</keyword>
  <keyword>food allergy/ hypersensitivity</keyword>
  <keyword>respiratory allergy/ hypersensitivity</keyword>
  <keyword>hymenopter allergy/ hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

